NCT04054024

Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia

A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Danish Headache Center · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

A placebo-controlled, double-blind, randomized proof-of-concept study to evaluate the efficacy and tolerability of the CGRP receptor antibody erenumab in treating pain experienced by subjects with TN.

Conditions

• Trigeminal Neuralgia

Interventions

Type	Name	Description
DRUG	Erenumab	140 mg Erenumab
DRUG	Placebos	Saline

Timeline

• Start date: 2019-10-28
• Primary completion: 2021-10-01
• Completion: 2021-10-01
• First posted: 2019-08-13
• Last updated: 2019-11-20

Locations

1 site across 1 country: Denmark

Regulatory

• FDA-regulated drug study